Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could this cell therapy free type 1 diabetes patients from insulin?

NCT ID NCT04786262

Disease control Sponsor: Vertex Pharmaceuticals Incorporated Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 02, 2026 · Updated 4 times

Summary

This study tests a treatment called VX-880 for people with type 1 diabetes who have dangerous low blood sugar episodes. The therapy uses donor cells that can produce insulin, aiming to let participants stop taking insulin shots and avoid severe hypoglycemia. About 52 adults with long-standing diabetes will receive the infusion and be monitored for safety and effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 57 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2021

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Clinical history of T1D with \>=5 years of duration of insulin dependence * At least two episodes of documented severe hypoglycemia in the 12 months prior to enrollment * Stable diabetic treatment * Consistent use of continuous glucose monitor (CGM) for at least 3 months before Screening and willingness to use CGM for the duration of the study Key Exclusion Criteria: -Prior islet cell transplant, organ transplant, or cell therapy Other protocol-defined Inclusion/Exclusion criteria may apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus, type 1 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypoglycemia type 1 diabetes mellitus type 1 diabetes mellitus 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus, type 1 Impaired hypoglycemic awareness Severe hypoglycemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    26 sites in 9 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Baylor Scott and White Research Institute

    RECRUITING

    Dallas, Texas, 75246, United States

  • CHU Lille

    RECRUITING

    Lille, France

  • Cardiovascular, Metabolic Medicine and Sciences, King's College London

    RECRUITING

    London, United Kingdom

  • Centre de recherche en Biomédecine de Strasbourg

    RECRUITING

    Strasbourg, France

  • Churchill Hospital

    RECRUITING

    Headington, Oxford, United Kingdom

  • City of Hope

    RECRUITING

    Duarte, California, 91010, United States

  • Dresden Center for Islet Transplantation

    RECRUITING

    Dresden, Germany

  • Hopiteaux Universitaires de Geneve

    COMPLETED

    Geneva, Switzerland

  • Hospital of the University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • IRCCS Ospedale San Raffaele

    RECRUITING

    Milan, Italy

  • Johns Hopkins University

    COMPLETED

    Baltimore, Maryland, 21287, United States

  • King Abdullah International Medical Research Center (KAIMRC) - Riyadh - Endocrinology

    RECRUITING

    Riyadh, Saudi Arabia

  • King Faisal Specialist Hospital & Research Centre - Riyadh - Endocrinology

    RECRUITING

    Riyadh, Saudi Arabia

  • Leiden University

    RECRUITING

    Leiden, Netherlands

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • McGill University Health Centre

    RECRUITING

    Montreal, Canada

  • Northwestern Organ Transplant Center

    COMPLETED

    Chicago, Illinois, 60611, United States

  • Oslo University Hospital

    RECRUITING

    Oslo, Norway

  • Royal Infirmary of Edinburgh

    RECRUITING

    Edinburgh, United Kingdom

  • The Newcastle upon Tyne Hospitals NHS Foundation Trust

    RECRUITING

    Newcastle upon Tyne, United Kingdom

  • Toronto General Hospital (TGH)

    RECRUITING

    Toronto, Canada

  • UHealth Diabetes Research Institute

    RECRUITING

    Miami, Florida, 33136, United States

  • University of Alberta, Edmonton

    RECRUITING

    Edmonton, Canada

  • University of California San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

  • University of Chicago

    RECRUITING

    Chicago, Illinois, 60637, United States

  • University of Pittsburgh Medical Center Montefiore

    RECRUITING

    Pittsburgh, Pennsylvania, 15213, United States

  • University of Wisconsin

    RECRUITING

    Madison, Wisconsin, 53792, United States

  • VCU Medical Center, Richmond

    RECRUITING

    Richmond, Virginia, 23298, United States

  • Vancouver General Hospital

    RECRUITING

    Vancouver, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.